Statin diabetogenicity: guidance for clinicians

Area of Science:

• Cardiology
• Endocrinology
• Pharmacology

Background:

• Type 2 diabetes (T2D) is a significant independent risk factor for cardiovascular (CV) and cerebrovascular events.
• While glycaemic control is crucial for T2D management, it yields less CV risk reduction compared to lipid-lowering or antihypertensive therapies.
• Fasting plasma glucose (FPG) is a modest predictor of CV risk in non-diabetic individuals.

Purpose of the Study:

• To evaluate the role of statins in cardiovascular risk reduction in patients with and without T2D.
• To investigate the conflicting data regarding the diabetogenic effects of statins.
• To determine if the cardiovascular benefits of statins outweigh their potential risks of inducing diabetes.

Main Methods:

• Meta-analysis of five randomized clinical trials involving 33,040 participants.
• Review of recent clinical trial data and US Food and Drug Administration (FDA) labeling changes for statins.
• Analysis of factors associated with statin-associated T2D, including baseline FPG, BMI, blood pressure, and triglycerides.

Main Results:

• Statins significantly reduce low-density lipoprotein-cholesterol levels and CV risk in individuals with and without T2D.
• The FDA now includes information on statins' effects on incident diabetes and glucose levels in their labeling.
• While some statins may increase HbA1c or FPG, their overall CV benefits are generally considered to outweigh diabetogenic risks.
• Specific statins like pitavastatin may have neutral or favorable effects on glucose control, unlike others such as atorvastatin under intensive therapy.

Conclusions:

• Conflicting data exist regarding the diabetogenic effects of statins, necessitating further research into drug-specific and patient-specific risks.
• Despite potential diabetogenic effects, statins should remain first-line therapy for most patients with dyslipidemia, metabolic syndrome, or T2D due to net CV benefit.
• Independent predictors for statin-associated T2D include elevated baseline FPG, BMI, blood pressure, and fasting triglycerides.